Notably, existing therapies, particularly monoclonal antibodies targeting CD20, are well-established in improving RA outcomes, this may explain why a GFD can protect against RA by acting on IgD+ CD38^dim B cells. The gene discussed is CD38; the disease is rheumatoid arthritis.